[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE067575T2 - Javított timidin-kináz gén - Google Patents

Javított timidin-kináz gén

Info

Publication number
HUE067575T2
HUE067575T2 HUE14769346A HUE14769346A HUE067575T2 HU E067575 T2 HUE067575 T2 HU E067575T2 HU E14769346 A HUE14769346 A HU E14769346A HU E14769346 A HUE14769346 A HU E14769346A HU E067575 T2 HUE067575 T2 HU E067575T2
Authority
HU
Hungary
Prior art keywords
improved
thymidine kinase
kinase gene
gene
thymidine
Prior art date
Application number
HUE14769346A
Other languages
English (en)
Inventor
John Levy
Rebecca Reed
Joseph Mcnulty
Robert Johnson
Original Assignee
Genvivo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvivo Inc filed Critical Genvivo Inc
Publication of HUE067575T2 publication Critical patent/HUE067575T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
HUE14769346A 2013-03-14 2014-03-14 Javított timidin-kináz gén HUE067575T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784901P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
HUE067575T2 true HUE067575T2 (hu) 2024-10-28

Family

ID=51569602

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14769346A HUE067575T2 (hu) 2013-03-14 2014-03-14 Javított timidin-kináz gén

Country Status (10)

Country Link
US (7) US9925276B2 (hu)
EP (2) EP2967078B1 (hu)
JP (5) JP2016524590A (hu)
CN (3) CN105555954B (hu)
AU (3) AU2014236208B2 (hu)
CA (2) CA2902875A1 (hu)
ES (2) ES2703341T3 (hu)
HU (1) HUE067575T2 (hu)
PH (3) PH12015502096A1 (hu)
WO (2) WO2014153205A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555954B (zh) 2013-03-14 2019-03-26 吉恩维沃公司 改进的胸苷激酶基因
WO2016100889A1 (en) * 2014-12-19 2016-06-23 Sutro Biopharma, Inc. Codon optimization for titer and fidelity improvement
GB2554639A (en) * 2016-09-28 2018-04-11 Univ Brunel Method of predicting the likelihood of success of gene therapy
CA3052505A1 (en) 2017-02-06 2018-08-09 University Of Ottawa Methods and compounds for detection and binding of aldehydes
WO2019020702A1 (en) 2017-07-26 2019-01-31 Medizinische Universität Wien THYMIDINE KINASE SUPERACTIVE FOR USE IN ANTICANCER THERAPY
CA3087175A1 (en) * 2017-12-28 2019-07-04 Bionoxx Inc. An oncolytic virus vector comprising c-terminally truncated herpes simplex virus-thymidine kinase (hsv-tk), compositions and methods of use thereof
WO2020165730A1 (en) * 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
EP3992281A4 (en) * 2019-06-27 2023-07-26 Bionoxx Inc. ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECT
CA3167002A1 (en) * 2020-01-09 2021-07-15 Pfizer Inc. Recombinant vaccinia virus
US11400039B2 (en) * 2020-01-16 2022-08-02 James W. Hill Changing eye color by gene transduction
IL299873A (en) * 2020-07-14 2023-03-01 Pfizer Recombinant VACCINIA virus
JP7564140B2 (ja) 2022-02-18 2024-10-08 株式会社Ｋｄｄｉ総合研究所 無線通信における高精度なチャネル推定を実行する制御装置、制御方法、及びプログラム
CN115414349B (zh) * 2022-08-26 2023-11-03 武汉科前生物股份有限公司 芹菜素在制备治疗猫鼻支气管炎药物中的用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
EP0845537A1 (en) 1989-08-18 1998-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
US6239351B1 (en) 1993-07-01 2001-05-29 Hoskins Manufacturing Company Multi-wire self-diagnostic thermocouple
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
US6033907A (en) * 1995-09-29 2000-03-07 Indiana University Foundation Enhanced virus-mediated DNA transfer
US6451571B1 (en) * 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
JPH10503641A (ja) * 1994-05-02 1998-04-07 ユニバーシティ オブ ワシントン チミジンキナーゼ変異体
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
EP0769968B1 (en) 1994-08-17 2005-01-26 Genetic Therapy, Inc. Retroviral vectors produced by producer cell lines resistant to lysis by human serum
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
ES2231819T3 (es) 1995-06-07 2005-05-16 Inex Pharmaceuticals Corp Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes.
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US5980935A (en) 1996-05-15 1999-11-09 Kirpotin; Dmitri Cationic lipids and methods of use therefor
US5962429A (en) 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
DE19651443A1 (de) 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
ES2303726T3 (es) * 1997-04-10 2008-08-16 University Of Southern California Proteinas modificadas que se fijan a componentes de la matriz extracelular.
ES2212305T3 (es) 1997-06-23 2004-07-16 Alza Corporation Polinucleotidos encapsulados en liposomas, composicion y procedimiento.
AU8428998A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
FR2766706B1 (fr) 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
DE69838483T2 (de) 1997-10-14 2008-07-03 Darwin Molecular Corp. Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
EP1914304A1 (en) 1998-10-14 2008-04-23 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
US6743631B1 (en) * 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy
ATE517999T1 (de) * 1998-04-24 2011-08-15 Onyx Pharma Inc Adenovirale vektoren zur behandlung der erkrankungen
DE19834430C2 (de) * 1998-07-30 2000-05-31 Harald Von Melchner Selbstdeletierende Vektoren für die Krebstherapie
US6490476B1 (en) * 1999-10-14 2002-12-03 Cti Pet Systems, Inc. Combined PET and X-ray CT tomograph and method for using same
US6825033B2 (en) * 2000-03-02 2004-11-30 University Of Southern California Mutated cyclin G1 protein
US20010046491A1 (en) 2000-03-23 2001-11-29 Valerie Kristoffer C. Tumor radiosensitization with mutant thymidine kinase in combination with a prodrug
RU2297453C2 (ru) * 2000-05-12 2007-04-20 Вольфганг КНЕХТ Вариант мультисубстратной дезоксирибонуклеозидкиназы, кодирующий его мутированный полинуклеотид, экспрессирующая векторная конструкция и их применение
CN1273587C (zh) * 2002-06-05 2006-09-06 上海新世界基因技术开发有限公司 疱疹病毒胸苷激酶突变体及其应用
US20050130132A1 (en) * 2002-09-06 2005-06-16 Day Craig H. Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2004041844A2 (en) * 2002-10-30 2004-05-21 Rigel Pharmaceuticals, Inc. Cell cycle targets and peptides
EP1619951B1 (en) 2003-04-21 2011-06-22 Epeius Biotechnologies Corporation Methods and compositions for treating disorders
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
CN1871034B (zh) * 2003-07-09 2011-07-06 亨利福特保健系统公司 用新型腺病毒治疗癌症的方法和组合物
US7815902B2 (en) 2003-07-09 2010-10-19 Henry Ford Health System Methods and compositions for cancer therapy using a novel adenovirus
DE102004039148A1 (de) 2004-08-12 2006-02-23 Clariant Gmbh Glühdrahtbeständige flammwidrige Polymere
WO2007109335A2 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California A method for noninvasively and quantitatively monitoring therapeutic and diagnostic transgene expression induced by ex vivo and in vivo gene targeting in organs, tissues and cells
CN100532544C (zh) * 2006-06-12 2009-08-26 山东省医药生物技术研究中心 逆转录病毒包装细胞系和肝细胞靶向性导入方法
WO2008140961A2 (en) 2007-05-08 2008-11-20 The Government Of The U.S.A, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus pseudoviruses for detection and therapy of tumors
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
US20100322861A1 (en) 2007-11-27 2010-12-23 Gambhir Sanjiv S Engineered cells, imaging report gene/probe systems, and methods of imaging
US20090176260A1 (en) * 2007-12-04 2009-07-09 Joseph Ching-Ming Wu Double-fusion human embryonic stem cells, methods of making double-fusion human embryonic stem cells, triple-fusion human embryonic stem cells, methods of making triple-fusion human embryonic stem cells, and methods of monitoring double-fusion human embryonic stem cells and triple-fusion human embryonic stem cells
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
EP2376518A4 (en) 2008-12-18 2013-12-04 Avaris Ab COMPLEX AND METHOD FOR AMPLIFYING NUCLEAR RELEASE
KR101032871B1 (ko) 2009-07-10 2011-05-06 주식회사 바이오드 비엠피-2와 에이치에스브이-티케이 자살유전자를 동시에 포함하고 발현 할 수 있도록 하는 벡터와 이 벡터가 도입된 자가조절형 줄기세포 치료제
JP2014504149A (ja) 2010-10-28 2014-02-20 ヴァージニア コモンウェルス ユニバーシティ 治療と併用する癌画像診断：セラノスティックス
US20130280170A1 (en) * 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
CN102801264B (zh) 2012-09-04 2015-02-11 魏乐汉 永磁叠层电机
US20140271640A1 (en) * 2012-12-07 2014-09-18 Permeon Biologics, Inc. FGF-10 Complexes
US20150307576A1 (en) 2012-12-07 2015-10-29 Permeon Biologics, Inc. Fgf-10 complexes
CN105555954B (zh) 2013-03-14 2019-03-26 吉恩维沃公司 改进的胸苷激酶基因

Also Published As

Publication number Publication date
CA2902975A1 (en) 2014-09-25
ES2703341T3 (es) 2019-03-08
CN110129344A (zh) 2019-08-16
PH12021550173A1 (en) 2022-02-14
US20200179533A1 (en) 2020-06-11
US20220401581A1 (en) 2022-12-22
JP2016519570A (ja) 2016-07-07
US11253611B2 (en) 2022-02-22
EP2967078A1 (en) 2016-01-20
JP7522543B2 (ja) 2024-07-25
CN105246337A (zh) 2016-01-13
US9925276B2 (en) 2018-03-27
JP2019219412A (ja) 2019-12-26
AU2020203408A1 (en) 2020-06-11
PH12015502096A1 (en) 2016-01-18
EP2967078A4 (en) 2016-10-26
EP2970945A2 (en) 2016-01-20
EP2970945B1 (en) 2024-05-01
WO2014153258A3 (en) 2015-01-08
US10350302B2 (en) 2019-07-16
EP2970945A4 (en) 2017-01-18
US20180264137A1 (en) 2018-09-20
PH12015502095B1 (en) 2016-01-18
US10610603B2 (en) 2020-04-07
NZ712211A (en) 2021-08-27
US20140288163A1 (en) 2014-09-25
WO2014153205A1 (en) 2014-09-25
JP2016524590A (ja) 2016-08-18
CN105555954A (zh) 2016-05-04
AU2014236208A1 (en) 2015-10-01
CA2902875A1 (en) 2014-09-25
US11364307B2 (en) 2022-06-21
NZ712210A (en) 2021-07-30
CN105555954B (zh) 2019-03-26
US20190328904A1 (en) 2019-10-31
JP7246343B2 (ja) 2023-03-27
US20180236101A1 (en) 2018-08-23
CN105246337B (zh) 2019-02-15
JP2022024006A (ja) 2022-02-08
CA2902975C (en) 2021-05-11
ES2981448T3 (es) 2024-10-08
AU2014236086B2 (en) 2020-03-05
EP2967078B1 (en) 2018-10-17
AU2014236086A1 (en) 2015-10-01
PH12015502095A1 (en) 2016-01-18
CN110129344B (zh) 2024-06-18
US20140294772A1 (en) 2014-10-02
NZ751656A (en) 2021-07-30
JP2020156501A (ja) 2020-10-01
AU2014236208B2 (en) 2018-07-19
WO2014153258A2 (en) 2014-09-25
AU2020203408B2 (en) 2023-01-12
US9999683B2 (en) 2018-06-19

Similar Documents

Publication Publication Date Title
HK1219021A1 (zh) 以類轉錄活化因子核酸酶為基礎的基因修正
HRP20182063T1 (hr) Gen otpornosti na rizomaniju
HUE067575T2 (hu) Javított timidin-kináz gén
SI2956477T2 (sl) Optimiran gen dejavnika VIII
GB201305407D0 (en) Media Distribution
GB2536367B (en) Directional casing-while-drilling
EP2979879A4 (en) PRINTER
GB201206455D0 (en) Gene expression
SG10201708046YA (en) Nanoprobe-Based Genetic Testing
GB201314376D0 (en) Cross Feeder
GB201310558D0 (en) Genetic test
GB201315774D0 (en) Prognostic gene
GB201315714D0 (en) DNA Construct
GB201309132D0 (en) Regulatable gene expression
GB201318949D0 (en) Genes
GB2516914B (en) Tile
HU4268U (en) Multi purposal glass-panel
GB201313563D0 (en) DNA Genetic test
GB201311420D0 (en) Quick change feeder
TWM476706U (en) Quick-easy pen
IL230049A0 (en) ink
AU2013064V (en) Flat Out Adenanthos cuneatus